TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05956769
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid injection 10 mg/kg and infusion 2 mg/kg/hr
Study: NCT05583188
Drug: Nivolumab plus Platinum Doublet Chemotherapy
Normalized name: platinum
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: If EGFR/ALK mutation negative, patients will receive standard of care dosing of three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) post-PEF ablation followed by resection.
Study: NCT00046033
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00046033
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00046033
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00046033
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00046033
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06258148
Drug: TG103
Normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TG103 injection, 7.5mg, 15 mg, SC, once a week
Study: NCT06361823
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.
Study: NCT04925063
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
Study: NCT06162286
Drug: Omadacycline
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline IV/PO
Study: NCT06162286
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin IV/PO
Study: NCT04796831
Drug: Quizartinib dihydrochloride
Normalized name: QUIZARTINIB DIHYDROCHLORIDE
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)
Study: NCT04796831
Drug: 14C-Quizartinib solution for infusion
Normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion
Study: NCT00038922
Drug: rhIL-11
Normalized name: Oprelvekin (rhIL-11)
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05321862
Drug: [68Ga]Ga-PentixaFor
Normalized name: [68Ga]Ga-PentixaFor
DrugBank: Boclatixafortide gallium Ga-68 (DB19176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomography by Emission of Positons (PET) with the radiopharmaceutic \[68Ga\]Ga-PentixaFor
Study: NCT00755066
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 µg intranasal, 4 weeks, od.
Study: NCT04685876
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-quadrant TAP block with liposomal bupivacaine
Study: NCT04685876
Drug: Plain bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-quadrant TAP block with plain bupivacaine
Study: NCT05340153
Drug: Dihydroartemisinin-Piperaquine drug combination
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine is a formulated as tablets and will be provided in blister packs. Each tablet contains 40 mg dihydroartemisinin and 320 mg piperaquine. Every pack has a picture showing how the drug should be given and contains 1 blister of 6 tablets. It will be given each day as a half, one, two or three tablets depending on the weight of the child.
Study: NCT05112666
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK.
Study: NCT04935476
Drug: Dapsone 85 mg PO BID
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive standard of care and study medication Dapsone 85 mg per os (PO) twice daily for 21 days. If a dose is missed, it will not be replaced.
Study: NCT05605665
Drug: low-dose interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU once twice a week, for 12 weeks.
Study: NCT05605665
Drug: rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rapamycin 0.5ml was taken orally once per day
Study: NCT05709184
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ten days of oral vancomycin 125 mg four times daily
Study: NCT05355844
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide application in the incision area before surgery
Study: NCT06243133
Drug: clopidogrel for 90 days combined with aspirin for 90 days
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 300mg on the first day, then 75mg/day for 90 consecutive days; Aspirin 100mg/day for 90 days
Study: NCT06243133
Drug: clopidogrel for 30 days combined with aspirin for 90 days
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 300mg on the first day, then 75mg/ day for 30 consecutive days; Aspirin 100mg/ day for 90 days
Study: NCT05516251
Drug: Topiramate 25Mg Tab
Normalized name: TOPIRAMATE 25MG TAB
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 25Mg Tab (Tuotai Pian, Xian Janssen Pharmaceutical Ltd.) are prescribed to participates by one neurologist. Participates are asked to take 25mg oral per day in a fixed time usually in the morning.
Study: NCT05830630
Drug: Bupivacaine methylene blue
Normalized name: Methylene Blue
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml methylene blue 1% (10 mg) plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of methylene blue plus bupivacaine 0.25% (1 ml of methylene blue added to each 49 ml of bupivacaine 0.25%) will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively
Study: NCT05830630
Drug: bupivacaine saline
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive the following regimen through the perineural catheter:~Bolus dose of 1 ml normal saline plus 19 ml bupivacaine 0.25% will be given intraoperatively before wound closure, and perineural infusion of bupivacaine 0.25% will be started in the recovery room at a rate of 2-5 ml/hour for 72 hours postoperatively
Study: NCT05466578
Drug: abrocitinib
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05418452
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin (MF), an antidiabetic agent, has been successfully used as a local drug delivery agent in periodontitis patients. Literature has suggested that MF possesses the osteogenic potential and induces the growth of osteoblast precursor cells. Therefore, several human studies have reported the use of MF alone or combined with PRF in the treatment of bony defects
Study: NCT04583813
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 10 mg oral tablet, once daily, for 24 months
Study: NCT05322187
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential PD-1/PD-L1 Inhibitor and LENvatinib treatment after chemotherapy resistance
Study: NCT04550624
Drug: Pembrolizumab Injection [Keytruda]
Normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg IV on day 1 of each cycle
Study: NCT04550624
Drug: Lenvatinib Mesylate
Normalized name: Lenvatinib Mesylate
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20mg PO daily days 1-21 of each cycle
Study: NCT06288516
Drug: Benralizumab 30 mg/ml
Normalized name: benralizumab 30 MG/ML
DrugBank: Benralizumab (DB12023)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks
Study: NCT00915668
Drug: JNJ-31001074
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04894617
Drug: Amantadine
Normalized name: Amantadine
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg Amantadine daily for a total of 5 days.
Study: NCT05604560
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Tislelizumab (200 mg intravenous) on Day 1 of Cycles 1-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
Study: NCT05604560
Drug: SX-682
Normalized name: SX-682
DrugBank: SX-682 (DB19210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive SX-682 (200 mg twice daily by mouth) on Days 1-14 of Cycles 1-2 and Days 1-21 of Cycles 3-6. Cycle 1 will be 14 days long and occur prior to surgery. Cycle 2 will be 14 days long and occur prior to standard of care chemotherapy. Cycles 3-6 will each be 21 days long and will be given after completion of standard of care chemotherapy.
Study: NCT06091553
Drug: Duloxetine alone
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg once daily for 1 week, then 60 mg once daily
Study: NCT06091553
Drug: Duloxetine augmented with gabapentin
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime
Study: NCT06091553
Drug: Duloxetine augmented with amitriptyline (as combined therapy)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily
Study: NCT05984134
Drug: NL005 Middle Dose
Normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.
Study: NCT05984134
Drug: NL005 High Dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this treatment group will receive NL005 for 1.5 ug/kg respective.Continuous administration for 7 days.
Study: NCT05435378
Drug: vitamin B9
Normalized name: Vitamin B9
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the non surgical treatment and the oral hygiene instructions the systemically administered vitamin B9 capsules will then given to the patients under the previously mentioned dosage.
Study: NCT04155008
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.
Study: NCT04155008
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
Study: NCT04155008
Drug: Mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.
Study: NCT05321394
Drug: Sotrovimab
Normalized name: SOTROVIMAB
DrugBank: Sotrovimab (DB16355)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Single intravenous infusion of sotrovimab 500 mg (500 mg/8 mL), administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour.
Study: NCT05321394
Drug: Tixagevimab Cilgavimab
Normalized name: tixagevimab
DrugBank: Cilgavimab (DB16393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 subsequent injections:~1. tixagevimab 300mg/3mL (100mg/mL)~2. cilgavimab 300mg/3mL (100mg/mL)
Study: NCT05321394
Drug: Nirmatrelvir Ritonavir
Normalized name: nirmatrelvir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg nirmatrelvir (two 150 mg tablets) with 100 mg ritonavir (one 100 mg tablet) with all three tablets taken together twice daily for 5 days
Study: NCT05432531
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction of remission of active lupus nephritis
Study: NCT05090761
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB
Study: NCT05090761
Drug: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate as adjuvant
Study: NCT05090761
Drug: Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 150 mg, Buprenorphine 300 mcg
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of Bupivacaine 0.25% Injectable Solution for SAPB Addition of 150 mg of Magnesium Sulfate and 300mcg Buprenorphine as adjuvants
Study: NCT00250692
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06087965
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 0.5mg/day oral fingolimod over a course of 3 consecutive days
Study: NCT04466475
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given via infusion
Study: NCT04590495
Drug: 300 mg Cannabidiol (CBD) oil
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will either be given a 300mg dosage of CBD oil. After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
Study: NCT05673538
Drug: TT-00973-MS tablets treatment
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose levels to be tested in the dose escalation cohorts are 2, 5, 10, 17, 25, 32, 40 and 50mg QD. All the subjects will receive TT-00973-MS tablets QD until disease progression or occurrence of intolerant adverse reactions.
Study: NCT04600167
Drug: Isoniazid and Rifapentine (INH-RPT)
Normalized name: Rifapentine
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
Study: NCT05028504
Drug: Penpulimab
Normalized name: Penpulimab
DrugBank: Penpulimab (DB16747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penpulimab is a humanized monoclonal antibody targeting programmed cell death-1 (PD-1), which prevents PD-1 from binding to PD-L1 and PD-L2 receptors on tumor cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT05028504
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A multi-target receptor tyrosine kinase inhibitor
Study: NCT04566328
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT04566328
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04566328
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06078657
Drug: IBI110+Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years.
Study: NCT05671276
Drug: aspirin and clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DAPT (until 6 months) + ASA
Study: NCT05671276
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: half-dose NOAC
Study: NCT05668767
Drug: Surufatinib Durvalizumab EP/EC
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide: total 100 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w; or Carboplatin: AUC 5-6, intravenous infusion, administered on day 1 of each treatment cycle, q3w
Study: NCT05181007
Drug: Valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valproate once daily on Day 4 to Day 8, Ciprofol on Day 1 and Day 8
Study: NCT05572983
Drug: Chidamide combined with CHOP
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po
Study: NCT05572983
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide: 20mg，qw（d1,d4）,po
Study: NCT00006279
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05770037
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adult participants will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Paediatric participants with a body weight ≥40 kg and who are able to swallow the capsules, will be administered alectinib orally at a dose of 600 mg (four 150 mg capsules) twice daily.~Each cycle of treatment will consist of 28 days and participants may continue on treatment until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT04835623
Drug: Cyclosporine 0.09% Ophthalmic Solution
Normalized name: Cyclosporine 0.09% Ophthalmic Solution
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop each eye twice daily
Study: NCT05657028
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: -In the Dexmedetomidine group, patients will be given IV bolus infusion of dexmedetomidine 0.5 μg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of dexmedetomidine 0.4 μg/kg/hour until 30 min before the end of surgery.
Study: NCT05657028
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the Lidocaine group, the patients will be given an IV bolus infusion of lidocaine (2%)1.5mg/kg over 10 min before induction of anesthesia, followed by a continuous IV infusion of lidocaine 1.5 mg/kg /hour until 30 min before the end of surgery.
Study: NCT05592015
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05272930
Drug: Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Assessment of fibromyalgia effects after the use of dienogest
Study: NCT05047991
Drug: Irinotecan Liposome Injection
Normalized name: Irinotecan liposome injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan Liposome Injection, intravenously, over 90 min on day 1and day 15 of every 28-day cycle